Swedish Orphan Biovitrum AB - Company Profile
Powered by 
All the data and insights you need on Swedish Orphan Biovitrum AB in one report.
$295
- Save hours of research time and resources with
our up-to-date Swedish Orphan Biovitrum AB Strategy Report
- Understand Swedish Orphan Biovitrum AB position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Business Description
Swedish Orphan Biovitrum AB (Sobi) develops innovative therapies and services for the treatment of rare diseases. It develops, manufactures, and commercializes specialist pharmaceuticals and protein-based medicines. It offers pharmaceutical products for the treatment of various diseases in the areas of hematology, inflammation, and autoimmune, inherited metabolic diseases, and cancer, among others. \
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Product Categories
Overview
Offers products for the treatment of Hemophilia. Major products include Elocta, Alprolix and Doptelet. Elocta is a recombinant clotting factor VIII therapy for hemophilia A. It is approved for the treatment of hemophilia A in adults and children of all ages and marketed by Sobi in the EU, Iceland, Liechtenstein, Norway, Switzerland, Kuwait and Saudi Arabia. Alprolix is a recombinant clotting factor therapy for Hemophilia B. It is approved for the treatment of hemophilia B in adults and children of all ages in the EU, Iceland, Liechtenstein, Norway, Switzerland, Kuwait and Saudi Arabia, marketed by Sobi. Doptelet is approved for the treatment of chemotherapy-induced thrombocytopenia (CIT). It focuses on expanding access to its extended half-life factor replacement treatments Elocta and Alprolix to reach more people with hemophilia A and B in other countries.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Offers products for the treatment of autoinflammatory diseases, inflammation and respiratory diseases. Major products include Synagis, Gamifant and Kineret. Synagis is indicated for the prevention of serious lower respiratory tract infections (LTRI) caused by RS-virus. Gamifant is indicated for the treatment of primary haemophagocytic lymphohistiocytosis (HLH). Kineret is indicated for the treatment of Still’s disease. Considers product innovations and geographical expansion as major factors for growth.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Focuses on rare diseases and niche indications such as hereditary tyrosinaemia type 1 (HT-1), rheumatoid arthritis, Dupuytren’s contracture and Peyronie’s disease. Major products include Orfadin, Kepivance and Ammonul, among others. It intends to acquire and license products with focus on rare diseases or niche indications.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Geographical Segments
Target Markets
France, Germany, Sweden, and Rest of Europe.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
It includes royalty related to its hemophilia products that are not attributable to a specific region. It refers to Sanofi’s sale of Eloctate and Alprolix.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward